An Open-label, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity and Maximum Tolerated Dose of OPB-31121 in Subjects with Advanced Leukemias or Myelodysplastic Syndromes.

Trial Profile

An Open-label, Non-randomized Study to Assess the Pharmacokinetics, Dose Limiting Toxicity and Maximum Tolerated Dose of OPB-31121 in Subjects with Advanced Leukemias or Myelodysplastic Syndromes.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2012

At a glance

  • Drugs OPB 31121 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Aug 2011 Planned end date changed from 1 Jul 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 25 Aug 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 26 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top